Talk:Personalized medicine

From Wikipedia, the free encyclopedia

	This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
B	This page has been rated as B-Class on the quality assessment scale
Mid	This article has been rated as Mid-importance on the importance assessment scale

[edit] "Genius"??

I think labeling a group of scientists and saying "employing the genius of ..." is a pretty clearly biased statement. They employed a bunch of scientists, fine, say that, but the word "genius" implies something about the problem - has anyone somehow done the research to show that these people are all very very smart? It seems like an unnecesarry term, in any event. —Preceding unsigned comment added by 128.189.132.69 (talk) 06:11, 29 November 2007 (UTC)

[edit] Gleevec

I disagree that use of imatinib mesylate (the real name of Gleevec) constitutes "personalised medicine". This is targeted therapy, but that is not the same as the loaded and horrible term "personalised medicine". It would be if every CML patient had his bcr/abl checked for particular resistance mutations and assigned imatinib, nilotinib or dasatinib as per the findings. That is not the case. JFW | T@lk 16:32, 27 September 2006 (UTC)

Unfortunately, I have to disagree with the previous post. Pesonalized medicine is about the right treatment, the right prevention, the right medicine, for the right person. Gleevec is a targeted therapy, in that it only works on "the right type" of cancer. Moreover it goes directly to the heart of what personalized medicine is. It is the moleculary evaluated patient, with the molecularly evaluated disease, and the molecularly designed treatment. Case in point: Gleevec, Tarceva, Amplichip all have pathophysiology molecularly evaluated, with molecularly evaluated patients, and although sometimes the medicines are used inappropriately by uneducated physicians, the majority are used appropriately on the the "right person". Most CML in the US is evaluated for the BCR-ABL fusion gene. Perhaps not in other countries, but absolutely in the US. So it should be included here. SARM | T@lk 09:32, 08 December 2006 (UTC)

I agree with JFW. Gleevec seems a lot closer to targeted therapy than to personalized medicine. I feel the same about Herceptin's inclusion. Under SARM's rather expansive definition of personalized medicine, you'd have to include HAART protocol changes based on viral resistance tests, and antibiotic selection based on what the bacteria seemed resistant to in culture. I don't think that anything which isn't one-size-fits-all should be lumped into "personalized medicine." WhatamIdoing (talk) 16:25, 7 December 2007 (UTC)

[edit] 'Stakeholder response'

Parts of this section feel to me like they're kinda choppy in terms of language and syntax. Also, the 'Patients' and 'Genetic Discrimination' headings seemingly disagree on whether the public seems to support genetic testing or not. Needs some clarification.

I didn't wanna edit it myself without saying something first. :-) 70.119.253.214 06:52, 3 November 2007 (UTC)